Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
The Consortium for Clinical Research and Innovation (CRIS) will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 to check if you are unsure if something is a scam or visit the ScamShield (opens in new tab) website for more information.

Consortium for Clinical Research and Innovation, Singapore (CRIS)
News

Media Coverage: CADENCE and Medera launch Asia’s first multi centre gene therapy trial for HF

19 November 2024

The launch of Asia's first multi-centre genre therapy trial received extensive scientific media coverage, highlighting Singapore’s robust cardiovascular research infrastructure and CADENCE’s efforts in streamlining clinical trial processes across these institutions.

Our programme, the Cardiovascular Disease National Collaborative Enterprise (CADENCE) and Medera Inc. (“Merdera”)’s Sardocor announced the initiation of a ground-breaking clinical trial for a novel gene therapy product aimed at treating heart failure (HF).

This marks the first multi-centre gene therapy trial in Asia for HF, with Singapore being the first and only site selected outside of the United States (US) for this significant translational breakthrough.

A composite of news articles announcing Asia's first multi-centre gene therapy clinical trial for heart failure in Singapore.

A selection of the media coverage can be accessed below: 

For more information, please refer to the following: